I would like to ask a brief follow-up question, Madam Chair.
It is curious what you're saying, which is that basically, it's only after a drug has come onto the market that we're following up on concerns. I know that the article in Maclean's pointed out that close to 20% of these new active substances are now being identified as problematic. It seems that we are taking too long to identify what the problems are. It's when they're on the market that adverse reactions are taking place. Again, there is a concern, first, that the study isn't taking place early enough, and second, that when there are adverse reactions, they're not being followed up. Now we see these stories, some of which are horrific, of people who have become sick or have died from some of these medicines.